We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Capricor Therapeutics Inc is a biotechnology business with stocks listed in the US. Capricor Therapeutics shares (CAPR) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$3.87 – a decrease of 2.27% over the previous week. Here's how to invest if you're based in Australia.
Our top pick for
US stocks
Our top pick for
ETF investing
Our top pick for
Overall broker
| 52-week range | US$3.13 - US$8.4 |
|---|---|
| 50-day moving average | US$4.3463 |
| 200-day moving average | US$4.3383 |
| Target price | US$13 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | US$-0.844 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Historical closes compared with the last close of $3.87
| 1 week (2021-10-19) | -2.27% |
|---|---|
| 1 month (2021-09-24) | -26.00% |
| 3 months (2021-07-26) | -19.04% |
| 6 months (2021-04-26) | -2.76% |
| 1 year (2020-10-26) | -11.44% |
|---|---|
| 2 years (2019-10-25) | 46.59% |
| 3 years (2018-10-26) | -42.07% |
| 5 years (2016-10-26) | -87.83% |
| Revenue TTM | US$319,591 |
|---|---|
| Gross profit TTM | US$-8,146,750 |
| Return on assets TTM | -29.75% |
| Return on equity TTM | -55.32% |
| Profit margin | 0% |
| Book value | 1.451 |
| Market capitalisation | US$87.9 million |
TTM: trailing 12 months
There are currently 1.2 million Capricor Therapeutics shares held short by investors – that's known as Capricor Therapeutics's "short interest". This figure is 60.8% up from 728,886 last month.
There are a few different ways that this level of interest in shorting Capricor Therapeutics shares can be evaluated.
Capricor Therapeutics's "short interest ratio" (SIR) is the quantity of Capricor Therapeutics shares currently shorted divided by the average quantity of Capricor Therapeutics shares traded daily (recently around 1.6 million). Capricor Therapeutics's SIR currently stands at 0.75. In other words for every 100,000 Capricor Therapeutics shares traded daily on the market, roughly 750 shares are currently held short.
However Capricor Therapeutics's short interest can also be evaluated against the total number of Capricor Therapeutics shares, or, against the total number of tradable Capricor Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Capricor Therapeutics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Capricor Therapeutics shares in existence, roughly 50 shares are currently held short) or 0.0521% of the tradable shares (for every 100,000 tradable Capricor Therapeutics shares, roughly 52 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Capricor Therapeutics.
Find out more about how you can short Capricor Therapeutics stock.
We're not expecting Capricor Therapeutics to pay a dividend over the next 12 months.
Capricor Therapeutics's shares were split on a 1:10 basis on 4 June 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Capricor Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Capricor Therapeutics shares which in turn could have impacted Capricor Therapeutics's share price.
Over the last 12 months, Capricor Therapeutics's shares have ranged in value from as little as US$3.13 up to US$8.4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Capricor Therapeutics's is 6.4587. This would suggest that Capricor Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Capricor Therapeutics, Inc., a biotechnology company, focuses on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase II clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with COVID-19; and completed various trials investigating the use of CAP-1002 for the treatment of cardiac conditions, including heart failure and post myocardial infarction with cardiac dysfunction. It is also developing CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in preclinical stage for the potential prevention of COVID-19. Capricor collaborates with Lonza Houston, Inc. for the development of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in Beverly Hills, California.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Shares in the wealth management giant have been largely stable in the last 6 months.
Everything we know about the Judo Capital Holdings IPO, plus information on how to buy in.
Everything we know about the Alloggio Group IPO, plus information on how to buy in.
Everything we know about the Larvotto Resources IPO, plus information on how to buy in.
Everything we know about the Vulcan Steel IPO, plus information on how to buy in.
Everything we know about the Artrya IPO, plus information on how to buy in.
Everything we know about the 8 Au IPO, plus information on how to buy in.
Everything we know about the Radiopharm Theranostics IPO, plus information on how to buy in.
The online retailer’s shares have lost more than half their value in the last 12 months.
